Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Checkpoint inhibitors for head and neck cancer in the definitive setting?

Barbara Burtness • 9 Nov 2018
ESMO 2018
Head and Neck Cancer Nivolumab Pembrolizumab

Barbara Burtness, MD, of Yale School of Medicine, New Haven, CT, talks about the current survival benefit of early pembrolizumab exposure in recurrent/metastatic head and neck squamous cell carcinoma (HNSCCO and its potential applications in definitive treatment. Its combination with chemo-radiation, along with other immune checkpoint inhibitors are currently being studied. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Barbara Burtness

OrigAMI-4: dual EGFR/MET targeting demonstrates durable responses in pretreated HNSCC
3:12
OrigAMI-4: dual EGFR/MET targeting demonstrates durable responses in pretreated HNSCC
Barbara Burtness • 1 Jun 2026
Key advances in head and neck cancer from ASCO 2026
2:49
Key advances in head and neck cancer from ASCO 2026
Barbara Burtness • 1 Jun 2026
Pembrolizumab plus CRT shows long-term benefit in PD-L1-rich HNSCC: KEYNOTE-412
3:29
Pembrolizumab plus CRT shows long-term benefit in PD-L1-rich HNSCC: KEYNOTE-412
Barbara Burtness • 1 Jun 2026
Current and upcoming clinical biomarkers for head and neck cancer
3:00
Current and upcoming clinical biomarkers for head and neck cancer
Barbara Burtness • 15 Apr 2026

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals